Presented by Decentralized Masters: Tan Gera, CFA Charterholder and ex-Wall Street investment banker, took $57k and turned it into $1.87M using BlackRock's system. Learn the exact three-phase framework he reverse-engineered →

Big Pharma is opening its wallet for cancer pipelines, and the premium being paid this morning is rippling straight into beaten-down biotech. Alongside it, money is rotating hard back into chips, with the memory and mobile names leading a broad semiconductor bid. The reward today is going to the acquired, the cyclical, and the dependable: a takeout target soaring on a buyout, the AI-trade names catching another wave, a household staples maker quietly clearing the bar.

The punishment is reserved for anyone who guided cautiously or missed the mark. A newly public software name is paying for a soft outlook, and a premium leisure operator is paying for an earnings miss. The throughline is simple: in this tape, the forward story matters more than the quarter you just printed.

Dear Reader,

I took $57,000 and turned it into $1.87 million in 18 months.

Not by trading. Not by luck.

By copying the three-phase system BlackRock uses to manage $14 trillion.

I'm Tan Gera, CFA Charterholder and ex-Wall Street investment banker.

I spent two years reverse-engineering BlackRock's exact playbook.

The same framework that generates them $16.1 billion in fees annually.

This system wasn't built for retail investors. It required millions in capital. It required institutional access.

So I rebuilt it for digital assets:

Protection when markets crash.

Income whether they go up or down.

Access to opportunities before they go public.

Over 4,500 investors are using this system now.

It works in any market conditions.

Bill turned $100k into $932k in 18 months. Mark paid off his entire membership in 90 days. Jeff made six figures on a single opportunity.

I call it the ABN System…

BlackRock's three-phase framework adapted for everyday investors with $50k+.

If you already hold digital assets, this system could multiply what you're sitting on right now.

Watch how to copy BlackRock's $14 trillion playbook →

To your wealth,

Tan Gera, CFA Decentralized Masters

P.S. I took $57k and turned it into $1.87M using BlackRock's system. Learn the exact three-phase framework I reverse-engineered →

Nuvalent (NUVL): +39%

The precision oncology name is soaring after UK pharma giant GSK agreed to buy it for $10.6 billion. That kind of premium speaks to how aggressively Big Pharma is paying up for late-stage cancer pipelines, and it puts a fresh bid under the whole small-cap biotech complex.

Micron Technology (MU): +5%

Chip stocks are extending their comeback, and Micron is leading the charge. When the memory names lead a rally, it usually signals that traders are betting the AI buildout still has room to run.

J.M. Smucker (SJM): +4%

The maker of Jif and Smucker's jam topped both earnings and revenue expectations for the quarter. In a tape that has punished consumer staples all year, a clean beat from a boring household name is exactly what defensive investors want to see.

Qualcomm (QCOM): +3%

The mobile chip giant is riding the semiconductor wave higher in premarket. The move is less about company news and more about sector rotation back into chips, with money flowing across the group.

SailPoint (SAIL): -12%

The identity security platform beat on the quarter but issued full-year guidance that landed at the low end of expectations. For a recently public software name still proving itself, the market cares far more about the forward outlook than the current quarter.

Vail Resorts (MTN): -5%

The mountain resort operator missed earnings estimates even as revenue came in line. When a premium-priced leisure name can't deliver on earnings, investors start questioning whether the consumer is still willing to pay up, and the stock pays the price.

Open your portfolio.

How much of it is in the same 5 stocks everyone owns?

In Q2 2026, that concentration risk is growing.

Meanwhile, most investors are still hiding in the same mega-caps.

That’s not an edge.

We screened the sub-$20 universe using three strict filters:

Only three stocks made the cut.

All under $20.

All fundamentally screened.

Not hype.

Not penny-stock gambling.

If market rotation accelerates, these are the types of names that historically benefit first.

👉 Access the free report here

Tilray Brands (TLRY)

Cannabis is one of the loudest corners of retail right now, with the broader US cannabis ETF hitting 2026 highs and StockTwits chatter around the sector sitting at bullish sentiment. Traders are circling Tilray as one of the most liquid, NASDAQ-listed ways to play a possible regulatory shift, and the company has signaled it may use recent capital raises to chase acquisitions if reform momentum holds.

The catalyst everyone is watching is a DEA administrative hearing scheduled for June 29, which will weigh whether broader adult-use cannabis should move to Schedule III after medical products already made that jump in April. The stock has been beaten down hard over the past year, so this hearing could be the event that either reignites the rescheduling trade or takes the air back out of it.